Literature DB >> 12754411

Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells.

Shin-Hae Kang1, Ji-Hoon Song, Hee-Kyoung Kang, Ji-Hoon Kang, Se-Jae Kim, Hyun-Wook Kang, Young-Ki Lee, Deok-Bae Park.   

Abstract

Arsenic trioxide (As(2)O(3)) has been found to be remarkably effective in the treatment of patients with acute promyelocytic leukemia (APL). Although evidences for the proapoptotic activity of As(2)O(3) have been suggested in leukemic and other solid cancer cells, the nature of intracellular mechanisms is far from clear. In the present study, we investigated As(2)O(3) affect on the stress-responsive signaling pathways and pretreatment with antioxidants using HepG2 cells. When treated with micromolar concentrations of As(2)O(3), HepG2 cells became highly apoptotic paralleled with activation of caspase-3 and members of mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK) and c-jun NH(2)-terminal kinase (JNK) but not p38 MAP kinase. However, inhibition of each kinase activity failed to inhibit apoptosis by As(2)O(3). Addition of n-acetyl cysteine (NAC) or diphenyleneiodonium (DPI) effectively protected cells from apoptosis and significantly lowered As(2)O(3)-induced activation of caspase-3. However, neither NAC nor DPI was able to effect ERK or JNK activation induced by As(2)O(3). Guanidinoethyldisulfide dihydrochloride (GED) and 2-ethyl-2-thiopseudourea (ETU), known inhibitors of the inducible nitric oxide synthase (iNOS), also suppressed the apoptotic activity of As(2)O(3). These results suggest that As2O3 induces caspase-mediated apoptosis involving a mechanism generating oxidative stress. However, activation of some stress-responsive signaling pathways by As(2)O(3) may not be the major determinant in the course of apoptotic processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754411     DOI: 10.1038/emm.2003.12

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  7 in total

1.  2,3,5,6-Tetramethylpyrazine (TMP) down-regulated arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF-κB, AP-1 and MAPK pathways in human proximal tubular cells.

Authors:  Xuezhong Gong; Vladimir N Ivanov; Tom K Hei
Journal:  Arch Toxicol       Date:  2015-09-24       Impact factor: 5.153

2.  Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide.

Authors:  Qin-Shu Shao; Zai-Yuan Ye; Zhi-Qiang Ling; Jin-Jing Ke
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

3.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

4.  Decreased glutathione levels potentiate the apoptotic efficacy of selenium: possible involvement of p38 and JNK MAPKs--in vitro studies.

Authors:  Pavitra Ranawat; M P Bansal
Journal:  Mol Cell Biochem       Date:  2007-11-08       Impact factor: 3.396

5.  Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.

Authors:  Toshiki Nakaoka; Akinobu Ota; Takayuki Ono; Sivasundaram Karnan; Hiroyuki Konishi; Akifumi Furuhashi; Yukinobu Ohmura; Yoichi Yamada; Yoshitaka Hosokawa; Yoshiaki Kazaoka
Journal:  Cell Oncol (Dordr)       Date:  2014-03-06       Impact factor: 6.730

6.  The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide.

Authors:  Xuhua Duan; Tengfei Li; Xinwei Han; Jianzhuang Ren; Pengfei Chen; Hao Li; Shaojun Gong
Journal:  Oncotarget       Date:  2017-06-27

7.  Systematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor types.

Authors:  Wei Jiang; Ramkrishna Mitra; Chen-Ching Lin; Quan Wang; Feixiong Cheng; Zhongming Zhao
Journal:  Brief Bioinform       Date:  2015-12-09       Impact factor: 11.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.